SYRS Stock Financial Analysis - Syros Pharmaceuticals, Inc. (OTCPK) Stock

Overview

Syros Pharmaceuticals, Inc., based in the United States, operates within the biopharmaceutical sector, focusing on the development of treatments that control the expression of genes to address the root causes of diseases. The company leverages its proprietary gene control platform to design therapies for cancer and monogenic diseases. A key area of concentration is hematologic malignancies; notable projects include the development of SY-1425, a selective retinoic acid receptor alpha (RARα) agonist, and SY-2101, a novel form of arsenic trioxide. These investigational drugs exemplify Syros Pharmaceuticals' strategic emphasis on transforming gene control insights into new, more effective therapeutics. The firm is actively involved in both clinical and preclinical stages, with a mission to provide profound therapeutic benefits through pioneering genetic mechanisms.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Syros Pharmaceuticals, Inc. as of September 30, 2024 is 0.39 MM.
The operating income for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -111.52 MM.
The net income for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -97.81 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2024-09-30	0.39	-111.52	-97.81
2024-06-30	4.15	-117.62	-131.56
2024-03-31	6.98	-124.21	-144.49
2023-12-31	9.94	-126.50	-164.57
2023-09-30	8.80	-135.49	-104.96
2023-06-30	8.92	-133.15	-95.07
2023-03-31	12.37	-132.92	-93.30
2022-12-31	14.88	-126.36	-94.65
2022-09-30	23.44	-115.79	-113.69
2022-06-30	25.24	-112.76	-109.47
2022-03-31	24.13	-105.13	-97.48
2021-12-31	23.49	-99.42	-86.56
2021-09-30	21.39	-103.22	-92.88
2021-06-30	19.52	-95.30	-86.33
2021-03-31	17.54	-85.90	-81.04
2020-12-31	15.09	-82.30	-84.04
2020-09-30	9.90	-73.25	-73.64

Income Statement: EPS

The earnings per share basic for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -2.66.
The earnings per share diluted for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -2.66.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2024-09-30	-2.66	-2.66
2024-06-30	-3.88	-3.88
2024-03-31	-4.64	-4.64
2023-12-31	-5.81	-5.81
2023-09-30	-3.76	-3.76
2023-06-30	-4.06	-4.06
2023-03-31	-5.18	-5.18
2022-12-31	-7.49	-7.49
2022-09-30	-15.73	-15.74
2022-06-30	-17.32	-17.33
2022-03-31	-15.48	-15.48
2021-12-31	-13.84	-13.84
2021-09-30	-15.74	-15.74
2021-06-30	-15.78	-15.77
2021-03-31	-16.07	-16.07
2020-12-31	-18.25	-18.20
2020-09-30	-16.52	-16.52

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -100.02 MM.
The cash from investing activities for Syros Pharmaceuticals, Inc. as of September 30, 2024 is 1.95 MM.
The cash from financing activities for Syros Pharmaceuticals, Inc. as of September 30, 2024 is 43.16 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2024-09-30	-100.02	1.95	43.16
2024-06-30	-111.19	30.59	43.15
2024-03-31	-103.90	38.45	43.25
2023-12-31	-109.71	37.34	43.46
2023-09-30	-122.23	73.54	-10.62
2023-06-30	-126.16	51.09	131.45
2023-03-31	-129.95	34.05	131.09
2022-12-31	-123.06	67.19	131.04
2022-09-30	-114.95	29.22	141.84
2022-06-30	-107.29	5.73	-0.29
2022-03-31	-107.57	-45.01	0.01
2021-12-31	-99.54	-52.65	70.51
2021-09-30	-106.50	-52.44	181.22
2021-06-30	-93.62	-35.66	181.52
2021-03-31	-79.60	3.20	181.67
2020-12-31	-57.36	46.66	142.95
2020-09-30	-38.04	63.65	33.24

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/e for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -0.41.
The p/book for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -8.44.
The p/tbv for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -8.44.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2024-09-30	-0.41	-8.44	-8.44
2024-06-30	-1.06	10.17	10.17
2024-03-31		9.12	9.12
2023-12-31	-1.93	5.57	5.57
2023-09-30	-0.86	1.12	1.12
2023-06-30	-0.68	0.59	0.59
2023-03-31	-0.57	0.42
2022-12-31		0.56	0.56
2022-09-30		4.19	4.19
2022-06-30		0.96	0.96
2022-03-31	-0.85	0.86	0.86
2021-12-31	-2.17	1.90	1.90
2021-09-30	-3.22	2.14	2.14
2021-06-30
2021-03-31	-0.78	0.42	0.42
2020-12-31	-0.68	0.63	0.63
2020-09-30	-0.63	1.02	1.02

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -4.83.
The ebit (3y)/ev for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -4.28.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2024-09-30	-4.83	-4.28
2024-06-30	-1.30	-1.01
2024-03-31	-3.07	-2.15
2023-12-31	-0.80	-0.79
2023-09-30	-12.68	-12.93
2023-06-30	97.31	100.51
2023-03-31	1.30	1.25
2022-12-31	2.20	1.81
2022-09-30	-0.98	-0.83
2022-06-30	-3.11	-2.74
2022-03-31	-4.08	-3.83
2021-12-31	-0.73	-0.66
2021-09-30	-0.55	-0.50
2021-06-30
2021-03-31	0.68	0.62
2020-12-31	1.09	0.96
2020-09-30	2.76	2.58

Management Effectiveness

The roa for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -0.89.
The roe for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -3.62.
The roic for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -1.99.
The croic for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -0.57.
The ocroic for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -1.69.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2024-09-30	-0.89	-3.62	-1.99	-0.57	-1.69
2024-06-30	-0.70	-1.35	-1.88	-0.29	-1.35
2024-03-31	-0.67	-1.29	-2.09	-0.37	-1.39
2023-12-31	-0.37	-0.81	-1.06	-0.60	-1.24
2023-09-30	-0.75	-3.07	-0.70	0.41	-0.93
2023-06-30	-0.74	-3.01	-0.70	0.41	-0.93
2023-03-31	-0.62	-1.51	-0.55	0.21	-0.77
2022-12-31	-0.55	-1.07	-0.57	0.28	-0.58
2022-09-30	-0.53	-1.03	-0.59	0.29	-0.59
2022-06-30	-0.42	-0.75	-1.15	-1.07	-1.12
2022-03-31	-0.33	-0.58	-0.76	-1.20	-0.84
2021-12-31	-0.44	-1.03	-0.58	-0.54	-0.62
2021-09-30	-0.70	-1.88	-0.54	0.13	-0.48
2021-06-30	-0.58	-1.38	-0.44	0.27	-0.48
2021-03-31	-0.50	-1.06	-0.38	0.49	-0.37
2020-12-31	-0.56	-1.06	-0.54	0.84	-0.37
2020-09-30	-0.51	-0.78	-0.79	0.63	-0.41

Gross Margins

The gross margin for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -22.23.
The net margin for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -31.71.
The operating margin for Syros Pharmaceuticals, Inc. as of September 30, 2024 is -28.35.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2024-09-30	-22.23	-31.71	-28.35
2024-06-30	-13.90	-20.70	-17.79
2024-03-31	-9.88	-16.56	-12.73
2023-12-31	0.70	-11.93	-15.40
2023-09-30	1.00	-10.65	-14.92
2023-06-30	1.00	-10.65	-15.99
2023-03-31	1.00	-7.54	-11.52
2022-12-31	1.00	-4.85	-4.94
2022-09-30	1.00	-4.85	-5.35
2022-06-30	1.00	-4.34	-4.47
2022-03-31	1.00	-4.04	-4.36
2021-12-31	1.00	-3.69	-4.23
2021-09-30	1.00	-4.34	-4.83
2021-06-30	1.00	-4.42	-4.88
2021-03-31	1.00	-4.62	-4.90
2020-12-31	1.00	-5.57	-5.45
2020-09-30	1.00	-7.44	-7.40